Alimera Sciences, Inc. (NASDAQ:ALIM)

CAPS Rating: 2 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:12:18 PM : Underperform Start Price: $5.10 ALIM Score: +40.03

Short. Biopharma. $0 Revenues. Consistent share dilution.

Recs

0
Member Avatar rielfireflame (< 20) Submitted: 5/14/2013 12:01:17 AM : Outperform Start Price: $4.00 ALIM Score: -21.31

This stock has been growing over the past few weeks. It seems that the growth is constant and should continue to grow over the next few weeks.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:49:24 PM : Outperform Start Price: $4.23 ALIM Score: -51.84

went up 244% for portefeille.

Recs

0
Member Avatar trockn (< 20) Submitted: 3/10/2012 11:14:03 AM : Outperform Start Price: $4.00 ALIM Score: -45.96

This is a huge need in Ophthalmology patient care. Patients are enduring numerous injections into the eye to decrease edema and the progressive damage it can create. This time-released med will last a long time while decreasing risk and cost to the patient.

Recs

0
Member Avatar Jemabogado (< 20) Submitted: 11/13/2011 4:24:41 PM : Outperform Start Price: $2.03 ALIM Score: +45.43

European approval will help lift it from the basement of FDA rejection!

Recs

0
Member Avatar FUZZYMINKINS (< 20) Submitted: 5/21/2011 10:51:50 AM : Outperform Start Price: $8.42 ALIM Score: -106.07

Diabetes Diabetes Diabetes. americans are unhealthy

Recs

0
Member Avatar TMFBiologyFool (95.76) Submitted: 1/24/2011 1:47:55 PM : Outperform Start Price: $8.90 ALIM Score: -115.78

First FDA rejection was fairly benign. Investors will come back as second decision approaches.

Recs

0
Member Avatar Brent2223 (31.86) Submitted: 12/31/2010 10:51:37 AM : Outperform Start Price: $10.13 ALIM Score: -126.16

oversold on FDA news

Results 1 - 8 of 8

Featured Broker Partners


Advertisement